Rapid Spontaneous Tumor Regression Mimicking Pseudoprogression in Pembrolizumab-treated Non-small Cell Lung Cancer.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 41363948.
- Also identified by DOI 10.1097/RLU.0000000000006228.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Atypical tumor responses can occur during immune checkpoint inhibitor therapy. A 71-year-old man receiving pembrolizumab treatment for stage IV non-small cell lung cancer was found on 18 F-FDG PET/CT to have developed new lesions in the stomach, left adrenal gland, and lungs. Because a gastric biopsy confirmed metastatic disease, treatment was discontinued. Remarkably, all lesions resolved after 4 weeks without any treatment. Pembrolizumab therapy was restarted, and follow-up CT showed further reduction in the lung cancer without new lesions. This case of spontaneous regression of gastric metastasis mimicking a pseudoprogression response to pembrolizumab treatment highlights the possibility of unusual presentations during immunotherapy.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Disease Progression
- Neoplasm Regression, Spontaneous